{"name":"Sino Biopharmaceutical","slug":"sino-biopharma","ticker":"1177.HK","exchange":"HKEX","domain":"sinobiopharm.com","description":"Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, benmelstobart injection under Andewei brand, unecritinib fumarate capsules under Anboni brand, envonalkib citrate capsule under Anluoqing brand, garsorasib tablets under Anfangning brand, bevacizumab injection under Anbeisi brand, culmerciclib capsule under Saitanxin brand, zongertinib tablets under Hernexeos brand, rovadicitinib tablet under Anxu brand,rituximab injection under Delituo brand, trastuzumab for injection under Saituo brand, and pertuzumab injection, under Paletan brand; liver disease medications, such as","hq":"Hong Kong / Nanjing, China","founded":2003,"employees":"21435","ceo":"Tse Ping (Chairman) / Tse, Theresa Y Y (CEO)","sector":"Oncology / Hepatitis / Respiratory","stockPrice":5.59,"stockChange":-0.06,"stockChangePercent":-1.06,"marketCap":"$14.7B","metrics":{"revenue":4691823311.105392,"revenueGrowth":9.8,"grossMargin":82.1,"rdSpend":0,"netIncome":345366771.24974334,"cash":3384101706.030244,"dividendYield":1.77,"peRatio":37.3,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"Sinomenine patent cliff ($100M at risk)","drug":"Sinomenine","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Sino Biopharmaceutical Reports 2023 Annual Results","summary":"The company reported a 15% increase in revenue and a 20% increase in net profit for the year 2023.","drugName":"","sentiment":"positive"},{"date":"2023-08-15","type":"deal","headline":"Sino Biopharmaceutical Partners with Chinese University to Develop New Cancer Therapies","summary":"The company has partnered with the Chinese University of Hong Kong to develop new cancer therapies using cutting-edge technologies.","drugName":"","sentiment":"neutral"},{"date":"2022-12-01","type":"regulatory","headline":"Sino Biopharmaceutical Receives Approval for New Hepatitis B Treatment in China","summary":"The company has received approval from the Chinese National Medical Products Administration for its new hepatitis B treatment.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxPNnR2M1lFY1hNeVdfRG1Ib2xxV296TEp2Wno3ekdvMUdFMGgyXzlweXFsNk9Gdy1tUHVVZVZkeGpDTUl3R2V1OFBSWjhEdUpobjBqVl8ySTRiUkJiRGFyakd5eXJzNzFtRHZGYUhFZG12VFZEVTBiV0Q1d1lSMWpIWk9JaXBkLWFI?oc=5","date":"2026-03-26","type":"pipeline","source":"The Standard (HK)","summary":"Chinese pharma shares slide - The Standard (HK)","headline":"Chinese pharma shares slide - The Standard (HK)","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-09","type":"pipeline","source":"simplywall.st","summary":"Assessing Sino Biopharmaceutical (SEHK:1177) Valuation After Sanofi Rovadicitinib Licensing Agreement - simplywall.st","headline":"Assessing Sino Biopharmaceutical (SEHK:1177) Valuation After Sanofi Rovadicitinib Licensing Agreement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxPSnZsY0xnVGhXYXlweXFHYmFCaHNWY2UtU2ZHV29EQWttYzRpRlV6UndpNmJRa2ZyaG81eUFfajRQNmFRVWdqRVRZZmUwZEVxU0ZUMDQ0LWRVQ3VmZ2tzYkhDOXNwZlBYYkkzcklOMWV2TngyWE1WSC1OcWhaaDZSeTFQNmxvOEdLc1VfeFhTMU95M1l6SmtMOTFpMy14YUYxS0lPTzlxeXFYdnh6R2lTWXJZankzR1dfMk5kV1ROUHIxQQ?oc=5","date":"2026-02-22","type":"pipeline","source":"Smartkarma","summary":"APAC Healthcare Weekly (February 22) – Sino Bio, Hansoh Pharma, Daiichi Sankyo, Ono, ABL Bio, CSL - Smartkarma","headline":"APAC Healthcare Weekly (February 22) – Sino Bio, Hansoh Pharma, Daiichi Sankyo, Ono, ABL Bio, CSL","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-10-19","type":"pipeline","source":"simplywall.st","summary":"Does Sino Biopharm Offer Value After Jumping 135% and Expanding in Asia in 2025? - simplywall.st","headline":"Does Sino Biopharm Offer Value After Jumping 135% and Expanding in Asia in 2025?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxObjhBZ2lrbVQta3RkdzRlQmFXQktjNFNsVXRWUDJPbFQzSURueDhJN21KZFRFVy1obkEzTDlFY0lWa0wwOVZibmI0ZTBTQU55NUZjWHBGclE1MmlCTWRvTlNmc1RzaDRyaXF3X1pweEo2b28wMzliTzJXZzV5cVJFNVZpR2VnUmd5VGpSSTJKalZpb0VKVnhtOVFwRFlXWHJJZGpiVGdqU1g0NE9nLVE?oc=5","date":"2025-03-20","type":"pipeline","source":"ACN Newswire","summary":"Sino Biopharm (1177.HK) Announces 2024 Annual Results - ACN Newswire","headline":"Sino Biopharm (1177.HK) Announces 2024 Annual Results","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxPZFd0M1hNSFZ2NmxJU21PLXphbHk1MmVncUZCYW84bmlVVU9KajBCQjJPNDhHaXh0WE1qbi0yeUprMllwYkhybjQtbUVjcXVBa0czZFBEN3pva3ZscWo5WW5IQTFIS185blhnYnhwUDUyZU1KNjJoeU03YXdqYW84Vi1nM2xHNVc5MlE?oc=5","date":"2024-12-19","type":"pipeline","source":"thebambooworks.com","summary":"Hengrui Pharma accelerates bid for global brand status - thebambooworks.com","headline":"Hengrui Pharma accelerates bid for global brand status","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxQOEdlOVllREVGZ0w5Q01qcjZJTGUxWlBWQVNOcmM4SjQtWHZ1dW5WLVkzU1FvcERkUGp5dmhwWko2SGgzNHlxbkMwTEdseHFLWTRDSS1nOTRKYkI1MEU2MjRqTUR5Nld3R3p1X3BWRi1vN2lKeVR4XzMxRVM5MWMwNFR5RF8yeVU0OUFqNlFDc2FsVlk?oc=5","date":"2024-08-29","type":"earnings","source":"thebambooworks.com","summary":"Novel drugs lift Sino Biopharm earnings, easing price-cap pain - thebambooworks.com","headline":"Novel drugs lift Sino Biopharm earnings, easing price-cap pain","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxNZ3hLaHFSV0F1cWxzeEcteDItdGxwUDdYSkRZZEplcjE1bnNCVEV0THpXSlo4VHpwVUY3d0tvUFp4LXdfeklfcEtETmJZT3pKcjRsZFpzbkVXY3hFTGlyUWozclVCb0dmVnZWcWw0aFlicV9UQ0JFQTA4aGNLVllITThvNW9NTFdxOGluYlRINGt3WTBqci0yeDRiSERuMlBHcmJUSzQ4WGxwOWFJc1E?oc=5","date":"2024-03-29","type":"pipeline","source":"ACN Newswire","summary":"Sino Biopharm (1177.HK) Announces 2023 Annual Results - ACN Newswire","headline":"Sino Biopharm (1177.HK) Announces 2023 Annual Results","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTFBFSXBCZUdUczBwZ08wa0o2b3dxR0tHZVFOSW1fVDZXYTVxNXhNSUg0T1JlUy1KTmVKSTBudUI2M1lGZVAwU2hIVjRxZ0pYaGI4TU0w?oc=5","date":"2023-03-31","type":"pipeline","source":"firstwordpharma.com","summary":"Sino Biopharm (1177.HK) Announces 2022 Annual Results - firstwordpharma.com","headline":"Sino Biopharm (1177.HK) Announces 2022 Annual Results","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwJBVV95cUxQQ0ZiZXY4aTdzYVU4dGRsWWFXcXZ6TERyWWZPd3l1a1VFYWRwVDZnOXBaQzJxcF93NUpFVE5kSDBQV3BBVEhXYlFpM3ZxUFhseTBNTWV6VDJVdjJUdl9XemY3dHV4YTVUcWdDc3FfeGlRT2JDbGxTOHFlNzQyaWdSNVlULUZoNUNhdGlQSWFBSEw2V09qWENzX0ZoTWhJTVVoWmNEYVV6Y0VFVFJHR1JKMnZNTTdUWVVscDN1bnNkNW1mQXJfb2JIU2NFZTdzcjhtNVIzMHJqY3M2S1lhdVQzXzlXTWFRTF9WUlMwQzNsQTl2NGMtaUFhUjBfcmtsX0Q3VFFuSFlDNlFNeGw3TnBpUEMtYnc5OFI1N19rSF9YRDhreDZQZ3Rr?oc=5","date":"2022-06-23","type":"deal","source":"GlobeNewswire","summary":"invoX Pharma to Acquire F-star Therapeutics, Inc. a - GlobeNewswire","headline":"invoX Pharma to Acquire F-star Therapeutics, Inc. a","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWkFVX3lxTE14WnZHRHdMY1llSm92VDhqdmtaaWhmNF8tWVVYZHMwOFN2aEtJaE5SNjFkMTZMU05pOVpxdDFjd285Z21IdzVCclhINmdQcWJOU0RGWW5ZeUpDdw?oc=5","date":"2017-08-02","type":"pipeline","source":"TradingView","summary":"1177 Stock Price and Chart — HKEX:1177 - TradingView","headline":"1177 Stock Price and Chart — HKEX:1177","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVkFVX3lxTE1WMEtoS1JqNVJZRk1RUC1UaklVZWpnQldRX2dva1Y5RmxuWkRONTBQMDZ0QVJTeER4THNLdHlOT1JCXzhZZjI1THN1a3lxMnpQeVE5OE13?oc=5","date":"2017-07-08","type":"pipeline","source":"Yahoo! Finance Canada","summary":"Sino Biopharmaceutical Limited (1177.HK) Stock Price, News, Quote & History - Yahoo! Finance Canada","headline":"Sino Biopharmaceutical Limited (1177.HK) Stock Price, News, Quote & History - Yahoo! Finance Canada","sentiment":"neutral"}],"patents":[{"drugName":"Sinomenine","drugSlug":"sinomenine","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":100000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":4,"keyCompetitors":["Hengrui Medicine","Jiangsu Hengrui Medicine","BeiGene"],"therapeuticFocus":["Oncology","Hepatitis","Respiratory"],"financials":{"source":"yahoo_finance","revenue":4691823188.48376,"revenuePeriod":"2025-12-31","revenueHistory":[{"period":"2025-12-31","value":4691823188.48376},{"period":"2024-12-31","value":4254345606.52143},{"period":"2023-12-31","value":3861315271.37393},{"period":"2022-12-31","value":3835782116.63028}],"grossProfit":3850606364.58396,"grossProfitHistory":[{"period":"2025-12-31","value":3850606364.58396},{"period":"2024-12-31","value":3467884352.57557},{"period":"2023-12-31","value":3125898367.03164},{"period":"2022-12-31","value":3174389327.4699597}],"rdSpend":864577276.59011,"rdSpendHistory":[{"period":"2025-12-31","value":864577276.59011},{"period":"2024-12-31","value":750055746.02931},{"period":"2023-12-31","value":648917954.00221},{"period":"2022-12-31","value":613771086.4014599}],"sgaSpend":1936125573.0448499,"operatingIncome":1016924338.42141,"operatingIncomeHistory":[{"period":"2025-12-31","value":1016924338.42141},{"period":"2024-12-31","value":933588643.0108399},{"period":"2023-12-31","value":897024552.30977},{"period":"2022-12-31","value":807623212.77308}],"netIncome":345366775.96595997,"netIncomeHistory":[{"period":"2025-12-31","value":345366775.96595997},{"period":"2024-12-31","value":515811729.62618},{"period":"2023-12-31","value":343685297.35203},{"period":"2022-12-31","value":374875848.71889997}],"eps":0.1298,"epsHistory":[{"period":"2025-12-31","value":0.1298},{"period":"2024-12-31","value":0.1913},{"period":"2023-12-31","value":0.1259},{"period":"2022-12-31","value":0.1215}],"cash":1795217399.91033,"cashHistory":[{"period":"2025-12-31","value":1795217399.91033},{"period":"2024-12-31","value":1410382228.08368},{"period":"2023-12-31","value":1393034509.46406},{"period":"2022-12-31","value":1778340418.66409}],"totalAssets":11202461956.363169,"totalLiabilities":4999763543.01238,"totalDebt":2368426665.09947,"equity":4520340077.63566,"operatingCashflow":1369445025.50317,"operatingCashflowHistory":[{"period":"2025-12-31","value":1369445025.50317},{"period":"2024-12-31","value":974948094.3623999},{"period":"2023-12-31","value":893978613.2691799},{"period":"2022-12-31","value":923369633.22435}],"capex":-250980690.20433,"capexHistory":[{"period":"2025-12-31","value":-250980690.20433},{"period":"2024-12-31","value":-205473768.4632},{"period":"2023-12-31","value":-251095647.98492998},{"period":"2022-12-31","value":-251376115.49324}],"freeCashflow":1118464335.29884,"dividendsPaid":-221463069.30873,"buybacks":-16211994.7,"employees":21435,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":5.59,"previousClose":5.65,"fiftyTwoWeekHigh":9.12,"fiftyTwoWeekLow":3.87,"fiftyTwoWeekRange":"3.87 - 9.12","fiftyDayAverage":5.88,"twoHundredDayAverage":6.87,"beta":0.64,"enterpriseValue":15565554128.61567,"forwardPE":18.1,"priceToBook":2.83,"priceToSales":3.13,"enterpriseToRevenue":3.32,"enterpriseToEbitda":14.56,"pegRatio":0,"ebitda":1069279199.649495,"ebitdaMargin":22.8,"freeCashflow":972909613.476526,"operatingCashflow":1369445033.7565491,"totalDebt":2368426647.4136577,"debtToEquity":38.2,"currentRatio":1.37,"returnOnAssets":5.6,"returnOnEquity":12.5,"analystRating":"1.2 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":19,"targetMeanPrice":8.89,"targetHighPrice":10.57,"targetLowPrice":7.13,"dividendRate":0.1,"payoutRatio":0.63,"fiveYearAvgDividendYield":1.83,"exDividendDate":1782259200,"insiderHeldPercent":48.5,"institutionHeldPercent":20.8,"sharesOutstanding":17849512337,"floatShares":8776429133,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":0.15,"epsForward":0.31,"revenuePerShare":1.77,"bookValue":1.98,"officers":[{"age":33,"name":"Ms. Y. Y.  Tse","title":"Executive Chairwoman of the Board"},{"age":29,"name":"Mr. S. Y.  Tse","title":"CEO & Executive Director"},{"age":73,"name":"Mr. Ping  Tse","title":"Founder & Senior Executive Vice Chairman"},{"age":61,"name":"Ms. Cheung Ling  Cheng","title":"Executive Vice Chairwoman of the Board"},{"age":61,"name":"Mr. Zhoushan  Tian","title":"Executive Director"},{"age":55,"name":"Mr. Hsin  Tse","title":"Senior VP & Executive Director"},{"age":49,"name":"Mr. Song  Jin","title":"Vice President of Public Affairs & ESG"},{"age":49,"name":"Ms. Xiaoyan  Kang","title":"Chief Medical Officer"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.sbpgroup.com","phone":"852 2802 9886"}}